Toripalimab Plus Chemotherapy for Advanced HER2-Negative Breast Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of toripalimab (an immunotherapy drug) with chemotherapy to treat advanced breast cancer that is HER2-negative. The goal is to see if this combination can help slow or stop cancer growth in patients who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-negative breast cancer that is advanced (locally advanced or spread to other parts of the body)
- Your cancer has progressed despite at least one prior treatment (chemotherapy and/or hormone therapy, depending on cancer subtype)
- You have adequate organ function (normal blood counts, liver, and kidney function)
- You are 18 years or older and able to attend all study visits
- You do not have uncontrolled brain metastases, active heart disease, or uncontrolled autoimmune conditions
- If of child-bearing potential, you agree to use effective contraception and have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining an immunotherapy drug (toripalimab) with targeted radiation (SBRT) can help people with triple-negative breast cancer that did not shrink after initial chemotherapy. It aims to improve outcomes before surgery.
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
This study tests a combination of an immunotherapy drug (toripalimab) and a targeted type of radiation called SBRT for breast cancer that didn't shrink with standard chemo. It aims to see if this combination can help your body fight the cancer better.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This trial tests a combination of two drugs (trastuzumab rezetecan and toripalimab) given before surgery to treat a specific type of breast cancer that is hormone-receptor-positive and HER2-low. It aims to see if this treatment can improve outcomes for patients who have not had prior cancer treatment.
This trial tests a combination of high-intensity focused ultrasound (HIFU, a non-invasive treatment that uses sound waves to heat and destroy tumor tissue) with the immunotherapy drug toripalimab and standard chemotherapy before surgery for women with a specific type of breast cancer (ER-positive, HER2-negative). The goal is to see if this approach can improve treatment outcomes for women with high-risk disease.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.